Derrick Gingery
a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation
phase III clinical trial summarization is underway. Ultra-rapid lispro is in the process of phase III clinical screening and enrollment. BC Combo, a soluble insulin glargine/lispro injection
GLP-1 RAsCombination therapyRandomized controlled trialsGlycemic controlType 2 diabetesMeta-analysisWe provided an updated systematic review with meta-analysis of randomized controlled trials (RCTs) assessing the metabolic effects of combination therapy of insulin and GLP-1RA (combo) in comparison with ...
following groups: (1) untreated, lean LETO (n=7), (2) untreated, obese OLETF (n=9), (3) OLETF + angiotensin receptor blocker (ARB; 10 mg olmesartan /kg/d; n=9), (4) OLETF + GLPmimetic (EXE; 10 ug exenatide/kg/d; n=7), and (5) OLETF + ARB + exenatide (Combo; n=6)...
Ninety-three participants completed the study. In the intention-to-treat analysis of all 107 subjects, the insulin sensitivity index did not improve in the exercise-alone group or the controls. This index did improve on average by 40 percent in the diet group and by 70 percent in the combine...